Triflupromazine and Trifluoperazine: Two New Tranquilizers

Rudy, Lester H.; Rinaldi, F; Costa, Emmanoel V.; Himwich, Harold E.; Tuteur, Werner; Glotzer, Jana

doi:10.1176/ajp.114.8.747-a

Cited by 14 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall CV for injected triflupromazine hydrochloride was 121% indicating that its dosing estimates are imprecise and unreliable. Triflupromazine is an aliphatic phenothiazine, similar to chlorpromazine, first used clinically in the 1950s ( Rudy et al, 1958 ). It has a WHO DDD of 100 mg for both its oral and SAI formulations ( WHO, 2023 ).…”

Section: Discussionmentioning

confidence: 99%

Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)

McAdam,

Baldessarini,

Murphy

et al. 2023

J Psychopharmacol

View full text Add to dashboard Cite

Background: Expert consensus-based clinically equivalent dose estimates and dosing recommendations can provide valuable support for the use of drugs for psychosis in clinical practice and research. Aims: This second International Consensus Study of Antipsychotic Dosing provides dosing equivalencies and recommendations for newer drugs for psychosis and previously reported drugs with low consensus. Methods: We used a two-step Delphi survey process to establish and update consensus with a broad, international sample of clinical and research experts regarding 26 drug formulations to obtain dosing recommendations (start, target range, and maximum) and estimates of clinically equivalent doses for the treatment of schizophrenia. Reference agents for equivalent dose estimates were oral olanzapine 20 mg/day for 15 oral and 7 long-acting injectable (LAI) agents and intramuscular haloperidol 5 mg for 4 short-acting injectable (SAI) agents. We also provide a contemporary list of equivalency estimates and dosing recommendations for a total of 44 oral, 16 LAI, and 14 SAI drugs for psychosis. Results: Survey participants ( N = 72) from 24 countries provided equivalency estimates and dosing recommendations for oral, LAI, and SAI formulations. Consensus improved from survey stages I to II. The final consensus was highest for LAI formulations, intermediate for oral agents, and lowest for SAI formulations of drugs for psychosis. Conclusions: As randomized, controlled, fixed, multiple-dose trials to optimize the dosing of drugs for psychosis remain rare, expert consensus remains a useful alternative for estimating clinical dosing equivalents. The present findings can support clinical practice, guideline development, and research design and interpretation involving drugs for psychosis.

show abstract

Section: Discussionmentioning

confidence: 99%